ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities), Step 3 was released for public comment on 16 June 2011. This guideline describes approaches to developing process and drug substance understanding, and also provides guidance on what information should be provided in CTD sections 3.2.S.2.2 – 3.2.S.2.6. It provides further clarification on the principles and concepts described in ICH guidelines on Pharmaceutical Development (Q8 R2), Quality Risk Management (Q9) and Pharmaceutical Quality System (Q10) as they pertain to the development and manufacture of drug substances. ICH guideline Q11 on development and manufacture of drug substances.
Broadening Pharmaceutical Training Footprint in Europe
Tuesday, 24 May 2016 19.05
Quality Manufacturing Leaders Shaping Regulatory & Compliance Landscapes
Monday, 23 May 2016 14.05
Explore the Future of Pharmaceutical Production
Thursday, 19 May 2016 13.05